SecBot SecBot
8-K ·Filed Feb 25, 2026

IMCR

Immunocore Holdings plc
BULLISH
Impact 7/10
Horizonweeks Processed8mo ago SEC0001140361-26-006721
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The stock may react positively to the strong revenue growth and improved profitability, but investors should monitor the expected moderating growth in 2026 and await key clinical data readouts in H2 2026 for brenetafusp and HIV programs.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$32.16
T+0 close · Feb 25, 2026 · via day close
Latest settled
−8.15%
T+60 · $29.54
Vs SPY
−15.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 25 $32.16entry
  2. T+1 · 9mo ago −0.37%α +0.17% · $32.04
  3. T+5 · 9mo ago +4.88%α +5.98% · $33.73
  4. T+20 · 8mo ago −5.85%α −0.61% · $30.28
  5. T+60 · 6mo ago −8.15%α −15.10% · $29.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK net sales of $104.5 million and $400.0 million respectively, representing 24% and 29% year-over-year growth. The company reduced its net loss from $51.1 million in 2024 to $35.5 million in 2025 despite increased R&D spending, and ended the year with $864.2 million in cash. Management expects moderating revenue growth in 2026 as it awaits key clinical data readouts.

Key Financial Metrics

Revenue
$400.0M
+29.0% YoY
EPS
$-0.71
Gross Margin
98.72%

Key Facts

  • KIMMTRAK net sales were $104.5 million in Q4 2025 (up 24% YoY) and $400.0 million for full year 2025 (up 29% YoY)
  • Net loss improved to $35.5 million in 2025 from $51.1 million in 2024 despite higher R&D expenses
  • Cash, cash equivalents and marketable securities totaled $864.2 million as of December 31, 2025
  • R&D expenses increased to $274.9 million in 2025 from $222.2 million in 2024 due to autoimmune programs and Phase 3 trials
  • Company expects moderating revenue growth in 2026 and anticipates key data readouts in second half of 2026

Financial Impact

$400 million in annual revenue with improving profitability and strong cash position

revenuenet losscashR&D expenses

Segment Breakdown

SegmentRevenueGrowth
KIMMTRAK$400.0M+29.0%

Risk Factors

  • Management expects moderating revenue growth in 2026
  • Key clinical data readouts in H2 2026 could impact the stock positively or negatively
  • Increased R&D spending could pressure margins if not offset by revenue growth

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-006721
Document: ef20066378_8k.htm0001140361-26-006721
Document: 0001140361-26-006721-index-headers.html0001140361-26-006721
Document: 0001140361-26-006721-index.html0001140361-26-006721
Document: 0001140361-26-006721.txt0001140361-26-006721

US Market Status

Market Closed · Opens in 8h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026